Articles
23 June 2009
Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
https://doi.org/10.4081/hmr.v2i5.736

Zanolimumab (HuMax-CD4®), a fully human monoclonal antibody in clinical development for cutaneous T-cell lymphoma

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
288
Views
349
Downloads

Authors

C Assaf
support@pagepress.org
Zanolimumab (HuMax-CD4®; Genmab, Copenhaven, Denmark) is a monoclonal human anti-CD4 antibody and specifically targets Thelper cells as well as CD4+ CTCL tumor cells and at a lower level monocytes and macrophages. Due to the interference with the interaction of the CD4 antigen and the major histocompatibility complex class II-molecule (MHC-II) this antibody is decreasing T-cell activation. In 2 phase II multicenter, prospective, open-label clinical trials the efficiency and safety of this anti-CD4 antibody was determined in relapsed early and advanced staged CTCL patients. 38 patients with MF and 9 patients with SS were treated intravenously with zanolimumab at a dosage of 280 mg or 560 mg for early stage patients and with 280 mg or 980 mg for advanced stage patients.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Zanolimumab (HuMax-CD4®), a fully human monoclonal antibody in clinical development for cutaneous T-cell lymphoma. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.736